Nanomedicine to Overcome Cancer Multidrug Resistance

被引:24
|
作者
Yang, Xi [1 ,2 ]
Yi, Cheng [1 ,2 ]
Luo, Na [3 ]
Gong, Changyang [1 ,2 ]
机构
[1] Sichuan Univ, West China Hosp, West China Med Sch, Dept Med Oncol,State Key Lab Biotherapy, Chengdu 610041, Peoples R China
[2] Sichuan Univ, West China Hosp, West China Med Sch, Ctr Canc, Chengdu 610041, Peoples R China
[3] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China
基金
中国国家自然科学基金;
关键词
Chemotherapy; drug delivery system; drug targeting; multidrug resistance; nanomedicine; tumor; MESOPOROUS SILICA NANOPARTICLES; TUMOR DRUG-RESISTANCE; CO-ENCAPSULATING DOXORUBICIN; P-GLYCOPROTEIN INHIBITOR; FOLATE RECEPTOR-ALPHA; SMALL INTERFERING RNA; BREAST-CANCER; ENHANCED PERMEABILITY; MACROMOLECULAR DRUGS; INTRACELLULAR DELIVERY;
D O I
10.2174/1389200215666140926154443
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer is still considered to be one of the most severe diseases so far. Multidrug resistance (MDR) is a major obstacle against curative cancer chemotherapy. The over-expression of drug efflux pumps in cellular membrane plays a critical role in preventing cancer cells from conventional chemotherapy. Nanotechnology is emerging as a class of therapeutics for MDR. This review mainly focuses on some pivotal strategies to combat MDR, including the enhanced permeability and retention (EPR) effect, stealth nanoparticles to prolong circulation time, endosomal escape, active drug delivery, stimuli sensitive drug release, and targeted co-delivery of different compounds. While convinced challenges need combatting, large numbers of preclinical studies strongly suggest that nanomedicine formations have potential application for improving the treatment of MDR.
引用
收藏
页码:632 / 649
页数:18
相关论文
共 50 条
  • [1] Insight on Multidrug Resistance and Nanomedicine Approaches to Overcome MDR
    Mohammad, Imran Shair
    He, Wei
    Yin, Lifang
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2020, 37 (05): : 473 - 509
  • [2] Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress
    Ortiz, Raul
    Quinonero, Francisco
    Garcia-Pinel, Beatriz
    Fuel, Marco
    Mesas, Cristina
    Cabeza, Laura
    Melguizo, Consolacion
    Prados, Jose
    CANCERS, 2021, 13 (09)
  • [3] Nanopreparations to overcome multidrug resistance in cancer
    Patel, Niravkumar R.
    Pattni, Bhushan S.
    Abouzeid, Abraham H.
    Torchilin, Vladimir P.
    ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (13-14) : 1748 - 1762
  • [4] Nanomedicine against multidrug resistance in cancer treatment
    Gao, Jie
    Feng, Si-Shen
    Guo, Yajun
    NANOMEDICINE, 2012, 7 (04) : 465 - 468
  • [5] Recent Trends in Nanomedicine-Based Strategies to Overcome Multidrug Resistance in Tumors
    Khan, Muhammad Muzamil
    Torchilin, Vladimir P.
    CANCERS, 2022, 14 (17)
  • [6] Nanomedicine therapeutic approaches to overcome cancer drug resistance
    Markman, Janet L.
    Rekechenetskiy, Arthur
    Holler, Eggehard
    Ljubimova, Julia Y.
    ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (13-14) : 1866 - 1879
  • [7] Modulating ROS to overcome multidrug resistance in cancer
    Cui, Qingbin
    Wang, Jing-Quan
    Assaraf, Yehuda G.
    Ren, Liang
    Gupta, Pranav
    Wei, Liuya
    Ashby, Charles R., Jr.
    Yang, Dong-Hua
    Chen, Zhe-Sheng
    DRUG RESISTANCE UPDATES, 2018, 41 : 1 - 25
  • [8] Different strategies to overcome multidrug resistance in cancer
    Saraswathy, Manju
    Gong, Shaoqin
    BIOTECHNOLOGY ADVANCES, 2013, 31 (08) : 1397 - 1407
  • [9] Novel nanomedicines to overcome cancer multidrug resistance
    Su, Zhenwei
    Dong, Shaowei
    Zhao, Shan-Chao
    Liu, Kaisheng
    Tan, Yao
    Jiang, Xingyu
    Assaraf, Yehuda G.
    Qin, Bo
    Chen, Zhe-Sheng
    Zou, Chang
    DRUG RESISTANCE UPDATES, 2021, 58
  • [10] Modulating cancer multidrug resistance by sertraline in combination with a nanomedicine
    Drinberg, Velthe
    Bitcover, Rivka
    Rajchenbach, Wolf
    Peer, Dan
    CANCER LETTERS, 2014, 354 (02) : 290 - 298